GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

Samsung BioLogics Co (XKRX:207940) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


Samsung BioLogics Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.